Loomis, Sayles & Company
BPMC

Loomis, Sayles & Company’s Blueprint Medicines BPMC Stock Holding History

Loomis, Sayles & Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-325,815
Closed -$21.5M – 872
2022
Q3 		$21.5M Sell
325,815
-3,945
-1% -$253K 0.04% 205
2022
Q2 		$16.7M Sell
329,760
-108,262
-25% -$6.34M 0.03% 274
2022
Q1 		$28M Buy
438,022
+58,923
+16% +$4.23M 0.04% 241
2021
Q4 		$40.6M Sell
379,099
-10,229
-3% -$1.07M 0.05% 195
2021
Q3 		$40M Sell
389,328
-6,040
-2% -$562K 0.05% 199
2021
Q2 		$34.8M Sell
395,368
-8,034
-2% -$736K 0.04% 229
2021
Q1 		$39.2M Buy
403,402
+48,011
+14% +$4.79M 0.05% 192
2020
Q4 		$39.9M Sell
355,391
-2,097
-0.6% -$221K 0.05% 164
2020
Q3 		$33.1M Buy
357,488
+48,289
+16% +$3.72M 0.05% 158
2020
Q2 		$24.1M Buy
+309,199
New +$20.9M 0.04% 191
2020
Q1 		– Sell
-426,978
Closed -$34.2M – 727
2019
Q4 		$34.2M Sell
426,978
-12,302
-3% -$921K 0.06% 126
2019
Q3 		$32.3M Buy
439,280
+64,012
+17% +$5.53M 0.06% 130
2019
Q2 		$35.4M Buy
375,268
+4,501
+1% +$371K 0.07% 126
2019
Q1 		$29.7M Buy
370,767
+13,372
+4% +$988K 0.06% 135
2018
Q4 		$19.3M Buy
357,395
+273,142
+324% +$16.6M 0.05% 177
2018
Q3 		$6.58M Buy
+84,253
New +$5.86M 0.01% 447

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Loomis, Sayles & Company's BPMC Position: Q4 2022 in Review

Loomis, Sayles & Company sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 325,815 shares — an estimated $21.5M sold.

Loomis, Sayles & Company first reported a position in BPMC in Q3 2018 and held it in 16 quarters. The position peaked at $40.6M in Q4 2021. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Loomis, Sayles & Company reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 325,815 Blueprint Medicines shares in Q4 2022, an estimated $21.5M.
  • Loomis, Sayles & Company first reported a position in Blueprint Medicines in Q3 2018 and held it in 16 quarters.
  • Loomis, Sayles & Company's Blueprint Medicines position peaked at $40.6M in Q4 2021.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Loomis, Sayles & Company's 13F filing for Q4 2022, filed 10 Feb 2023.